Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor. Prediction of histology. ReHiT Study Group.
BACKGROUND
After chemotherapy for a metastatic nonseminomatous germ cell tumor, pulmonary masses may be seen on a computed tomography scan. These residual masses may contain one of three histologic elements: necrosis, mature teratoma, or cancer. Because surgical resection of masses containing only necrosis is unnecessary, the authors aimed to predict the histology of these residual masses.


METHODS
Six study groups contributed patient data on a total of 215 patients undergoing thoracotomy after cisplatin-based induction chemotherapy for metastatic testicular nonseminomatous germ cell tumors. Logistic regression analysis was used to estimate the probability of necrosis, mature teratoma, and cancer in relation to predictors known before thoracotomy.


RESULTS
The pulmonary mass histology was necrosis in 116 patients (54%), mature teratoma in 70 (33%), and cancer in 29 (13%). Necrosis was found at thoracotomy in 89% of those patients with necrosis at retroperitoneal lymph node dissection (RPLND). Other predictors included the primary tumor histology, prechemotherapy tumor marker levels, change in mass size during chemotherapy, and the presence of a single, unilateral mass. Multivariate combination of predictors yielded reliable models (goodness-of-fit tests, P > 0.20), which discriminated necrosis well from other histologies, especially if RPLND histology was available (area under the receiver operating characteristic curve, 0.86).


CONCLUSIONS
This analysis indicated subgroups of patients with a high probability of necrosis and a low risk of cancer for whom close follow-up of the residual pulmonary mass might be considered. In most patients, a RPLND should be performed before a thoracotomy is considered, because the probability of necrosis is generally higher at thoracotomy than at RPLND and the histology at RPLND is a strong predictor of the histology at thoracotomy.
Steyerberg
E W
EW
Department of Public Health, Erasmus University, Rotterdam, The Netherlands.
Keizer
H J
HJ
Messemer
J E
JE
Toner
G C
GC
Schraffordt Koops
H
H
Fosså
S D
SD
Gerl
A
A
Sleijfer
D T
DT
Donohue
J P
JP
Habbema
J D
JD
D000704:Analysis of Variance; D014408:Biomarkers, Tumor / Q000097:blood; D006063:Chorionic Gonadotropin / Q000097:blood; D018237:Germinoma / Q000097:blood / Q000188:drug therapy / Q000473:pathology* / Q000556:secondary* / Q000601:surgery; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008175:Lung Neoplasms / Q000097:blood / Q000188:drug therapy / Q000473:pathology* / Q000556:secondary* / Q000601:surgery; D008297:Male; D009336:Necrosis; D013724:Teratoma / Q000097:blood / Q000188:drug therapy / Q000473:pathology* / Q000556:secondary* / Q000601:surgery; D013736:Testicular Neoplasms / Q000473:pathology*; D000509:alpha-Fetoproteins / Q000032:analysis
D014408:Biomarkers, Tumor; D006063:Chorionic Gonadotropin; D000509:alpha-Fetoproteins; D007770:L-Lactate Dehydrogenase